Open AccessTowards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients
Author(s) -
Sophie Périnel,
Ma Launay,
Élisabeth Botelho-Nevers,
Éric Diconne,
Aurore Louf-Durier,
Raphaël Lachand,
Martin Murgier,
Dominique Page,
Régine Vermesch,
Guillaume Thierry,
Xavier Delavenne
Publication year - 2020
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa394
Subject(s) - hydroxychloroquine , dosing , medicine , covid-19 , pharmacokinetics , intensive care medicine , intensive care unit , regimen , clinical trial , pandemic , pharmacology , virology , disease , outbreak , infectious disease (medical specialty)
Hydroxychloroquine (HCQ) appears to be a promising treatment for COVID-19. However, all ongoing clinical trials with HCQ use different dosing regimens, resulting on various concentrations PK studies are therefore needed to define the optimal dosing regimen.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom